JOHNS HOPKINS UNIVERSITY

🇳🇦Namibia

Country: 🇳🇦Namibia

Ownership: -

Established: 1876-01-01

Employees: 19.4K

Market Cap: -

Website: https://www.jhu.edu/

Clinical Trials

Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy

Early Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Device: 3-D TRUS navigation software during T-RALP

First Posted Date: 2009-08-11

Last Posted Date: 2013-06-19

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 50

Registration Number: NCT00956904

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Transrectal Ultrasound Imaging of the Prostate Gland and Neurovascular Bundles During Robot-Assisted Laparoscopic Radical Prostatectomy

Early Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Device: TRUS-RALRP

First Posted Date: 2009-08-06

Last Posted Date: 2010-09-13

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 6

Registration Number: NCT00952666

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Pilot Study of the Modified Atkins Diet for Tourette Syndrome

Phase 1

Terminated

Conditions: Tourette Syndrome

Interventions: Dietary Supplement: Modified Atkins diet

First Posted Date: 2009-08-06

Last Posted Date: 2010-07-15

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 20

Registration Number: NCT00952601

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Potassium Intake in Patients With Chronic Kidney Disease

Not Applicable

Completed

Conditions: Chronic Kidney Disease
Hypertension

Interventions: Other: Dietary intake of potassium

First Posted Date: 2009-07-30

Last Posted Date: 2012-09-19

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 29

Registration Number: NCT00949585

Locations: 🇺🇸
Johns Hopkins University Pro Health Clinical Research Facility, Baltimore, Maryland, United States

Omalizumab in the Treatment of Peanut Allergy

Phase 2

Completed

Conditions: Food Allergy
Peanut Allergy

Interventions: Drug: omalizumab

First Posted Date: 2009-07-30

Last Posted Date: 2017-07-12

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 51

Registration Number: NCT00949078

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

Phase 2

Terminated

Conditions: Glucose Homeostasis

Interventions: Drug: Placebo
Drug: Januvia

First Posted Date: 2009-07-27

Last Posted Date: 2017-07-12

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 12

Registration Number: NCT00947011

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

ETV Versus Shunt Surgery in Normal Pressure Hydrocephalus

Terminated

Conditions: Hydrocephalus

Interventions: Procedure: Ventriculoperitoneal Shunt Placement
Procedure: Endoscopic Third Ventriculostomy(ETV)

First Posted Date: 2009-07-24

Last Posted Date: 2012-10-03

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 13

Registration Number: NCT00946127

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Relapse Prevention With Varenicline

Phase 4

Completed

Conditions: Substance-Related Disorders
Recurrence
Smoking Cessation

Interventions: Drug: Placebo
Drug: Varenicline

First Posted Date: 2009-07-23

Last Posted Date: 2017-08-03

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 104

Registration Number: NCT00944554

Locations: 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

Phase 2

Completed

Conditions: Sickle Cell Disease
Priapism

Interventions: Other: placebo
Drug: sildenafil

First Posted Date: 2009-07-17

Last Posted Date: 2017-04-13

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 13

Registration Number: NCT00940901

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis

Phase 2

Withdrawn

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Cyclophosphamide/Glatiramer acetate

First Posted Date: 2009-07-15

Last Posted Date: 2018-09-26

Lead Sponsor: Johns Hopkins University

Registration Number: NCT00939549

Locations: 🇺🇸
Johns Hopkins Hospital Multiple Sclerosis Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy